Price
No data yet.
Social Signal Score
Analyst Ratings
12 analystsRevenue
$0.00-100.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Andrew R. Robbins
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 258
- Beta
- 0.31
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 7.79
Financials
Revenue
$0.00-100.0%Net Income
$-96.41MEBITDA
$-94.45MFree Cash Flow
$-77.64MEPS (diluted)
$-0.52Shares Outstanding (diluted)
171.01M+4449.8%Operating Expenses
$102.64MCash & Debt
$792.30MRevenue by Segment (annual)
$25.00MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-328.94M | $-2.04 |
| 2024 | $0.00 | $-255.86M | $-2.32 |
| 2023 | $0.00 | $-192.41M | $-2.42 |
| 2022 | $0.00 | $-140.24M | $-2.26 |
| 2021 | $0.00 | $-72.27M | $-1.85 |
| 2020 | $7.87M | $-74.81M | $-6.00 |
| 2019 | $22.50M | $-30.27M | $-3.97 |
| 2018 | $9.73M | $-34.53M | $-5.55 |
| 2017 | $8.36M | $-25.49M | $-3.45 |
| 2016 | $6.36M | $-18.12M | $-3.10 |
| 2015 | $2.99M | $-6.59M | $-1.13 |
Valuation
COGThas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
10-80.00%Social Signal Score
Mentions (7)
- Newsglobenewswire.com·21d ago·Negative
Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) NDA supported by positive results from the APEX pivotal trial demonstrating clinically meaningful responses and evidence of disease modification in patients with AdvSM
View source ↗ - News (RSS)seekingalpha·27d ago·Positive
Cogent Communications Holdings, Inc. (CCOI) Presents at Goldman Sachs Communacopia + Technology Conference 2026 Transcript
View source ↗ - News (RSS)hellenicshipping·29d ago·Negative
Cosco readies for growth as efficient, reliable, end-to-end logistics provider in Southeast Asia After selling its loss-making shipyard and shipbuilding business in May 2017 to another subsidiary owned by its parent, Mainboard-listed Cosco Shipping International (Singapore) entered the logistics sector 10 months later when it completed the acquisition of established logistics provider Cogent Holdings in March 2018. “Through M&A, we could quickly obtain resources such as warehouses, but ...
View source ↗ - News (RSS)seekingalpha·39d ago·Neutral
Cogent Biosciences: 3 NDAs Create A Time-To-Market Moat
View source ↗ - Newsseekingalpha.com·40d ago·Neutral
Cogent Biosciences: 3 NDAs Create A Time-To-Market Moat Cogent Biosciences is positioned to commercialize bezuclastinib across three indications, leveraging a single precision molecule for multi-market entry. Positive pivotal data in GIST, NonAdvSM, and AdvSM underpin three NDAs, with regulatory decisions expected between late 2026 and early 2027. COGT's commercial infrastructure and $865.9M liquidity provide a runway through 2028, supporting launch and early commercialization activities.
View source ↗ - Newszacks.com·53d ago·Neutral
Cogent Biosciences (COGT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now Cogent Biosciences (COGT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
View source ↗ - News (RSS)seekingalpha·56d ago·Neutral
Cogent Biosciences reports Q2 results
View source ↗
Earnings
Fri, Nov 6(in 4 weeks)
Consensus estimate $-0.57 per share
Typical surprise +3.6% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 10$-0.52 vs $-0.55beat
- Tue, May 5$-0.53 vs $-0.53beat
- Tue, Feb 17$-0.55 vs $-0.51miss
- Fri, Nov 7$-0.50 vs $-0.54beat
- Tue, Aug 5$-0.53 vs $-0.55beat
- Tue, May 6$-0.52 vs $-0.56beat
Estimates and results for COGT via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by COGT officers and directors.
- Bought
- $34.9m
- Sold
- $383.9m
3 trades
8 trades
- Morris Arlenesold
- Morris Arlenesold
- Fairmount Funds Management Llcsold
- Fairmount Funds Management Llcsold
- Kearns Evansold
- Green John L.sold
- Sachs Jessicasold
- Robinson John Edwardsold
89 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Chris Jacobshouse · NY27 · disclosed Jan 20, 2023 (39d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.